CNE000000545
CNE000000545
VCANBIO CELL & GENE ENG CORP LT
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 8.94B EUR | 8.01B EUR | 14.46B EUR | 11.79B EUR |
Enterprise Value | 7B EUR | 6.79B EUR | 12.95B EUR | 10.85B EUR |
Valuation Multiples | ||||
Trailing P/E | 76.4x | 119.55x | 241.36x | 185.14x |
Forward P/E | 43.41x | -- | -- | -- |
Price to Sales | 6.39x | 7.84x | 13.83x | 10.93x |
Price to Book | 2.33x | 2.14x | 3.89x | 3.18x |
EV/Revenue | 5.01x | 6.65x | 12.39x | 10.06x |
EV/EBITDA | 29.93x | 47x | 83.97x | 68.42x |
Price to FCF (P/FCF) | 41.12x | 41.75x | 89.26x | 66.43x |
EV/FCF | 32.21x | 35.41x | 79.94x | 61.14x |
FCF Yield | 2.43% | 2.4% | 1.12% | 1.51% |